KCT0001086已完成未知
A randomized, open-label, multiple-dose, two-arm, one-sequence?crossover study to evaluate the safety and pharmacokinetics after oral concurrent administration telmisartan/s-amlodipine and rosuvastatin in healthy volunteers
Chong Kun Dang0 个研究点目标入组 64 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- All
入选标准
- •1. Participant is a male or female between 20 and 45 years of age (inclusive) at the pre-study (screening)
- •2. Participant who has a body weight that is >55kg(male) or >50kg(female) with ideal body weight of 80-120%
- •(ideal body weight) = {Height(cm) - 100} * 0.9
- •3.If female, must include more than one among the items
- •a.The menopause (there is no natural menses for at least 2 years)
- •b.Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
- •c.The male partner infertility before screening (Demonstrated azoospermia after vasectomy)and if this man is the only partner of the female subject.
- •d.you are using one of the following contraceptive measure for 3 months before screening, and Necessarily you agree that used continuously contraceptive measure during the clinical trial and for 1 month after the final dosing investigational product.(But, should not use a device of contraception or oral contraceptive drug that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium drug interactions during the clinical trials)
- •- Abstinence.
- •- Physical interrupt method (such as a condom, contraceptive diaphoretic or cervical cap)
- •e.In case of women of childbearing age, the serum ß-hCG pregnancy test is negative before taking the investigational product, and urine ß-hCG test is negative before taking the investigational product.
- •4.If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms during clinical trials and do not sperm donation during clinical trials and until one month after the final dosage of investigational products
- •5.Those who fully understand about this clinical trial after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent.
排除标准
- •1. The subject has a previous history of any clinically significant cardiovascular, pulmonary, renal, endocrine, hematological, gastro-intestinal, neurological, psychiatric, or malignancy.
- •2. Have a gastrointestinal disease history that can affect drug absorption (Crohn's disease, ulcers, etc.) or surgery (except simple appendectomy or hernia surgery).
- •3. Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction in the history of Investigational drugs (telmisartan, s-amlodipine or rosuvastatin calcium) or additives.
- •4. An impossible one who participates in clinical trial including screening tests(medical history taking, Vital sign, physical examination, 12-lead ECG, blood & urine laboratory test result)
- •5. Defined by the following laboratory parameters:
- •-Hemoglobin < 13.0 g/dL(male), Hemoglobin < 12.0 g/dL(female)
- •-Aspartate aminotransferase or Alanine aminotransferase> 1.25* upper limit of normal range
- •-Total bilirubin > 1.5* upper limit of normal range
- •-Creatinine phosphokinase > 1.5* upper limit of normal range
- •-estimated Glomerular filtration rate(using by MDRD method) < 60 mL/min/1.73m2
- •6.Sitting SBP > 150 mmHg or < 90 mmHg, Sitting DBP> 100 mmHg or < 50 mmHg , after 5minuts break.
- •7.Drug abuse or have a history of drug abuse showed a positive for urine drug test.
- •8. Female Participant is pregnant or lactating
- •9. A heavy caffeine consumer(caffeine>5cups/day), alcohol consumer(alcohol>210g/week), or smoker(cigarette>10cigarettes/day)
- •10. Participation in any other study and have received any other investigational drug or device within 90 days prior to study treatmen.
- •11. Administration of drug metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing.
- •12. Blood donation (1 unit or more) within 60 days prior to study treatment or plasma donation within 30 days prior to study treatment.
- •13. Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days before the beginning of study treatment)
- •14. Subject takes ethical drug or herbal medicine within 14days, Over the count medicine or vitamins within 7days before the beginning of study treatment.
- •15. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
研究者
相似试验
尚未招募
1 期
A randomized, open-labeled, multiple-dose, two-way crossover design with two-period, two-treatment, two-sequence steady-state bioequivalence study of Venlafaxine Hydrochloride Extended-Release Capsules 150 mg and Efexor XR 150 mg Capsules in healthy, adult, Thai volunteers under fed conditioHealthy subjectsBioequivalence Venlafaxine Hydrochloride Extended-Release Capsules 150 mgTCTR20240706012Bio-innova Co., Ltd.44
招募中
不适用
To investigate the pharmacokinetic drug interaction between Pitavastatin and Ezetimibe after oral administration in healthy volunteersEndocrine, nutritional and metabolic diseasesKCT0007827Kuhnil Pharm.56
已完成
不适用
Study to evaluate the safety and pharmacokinetics after co-administration of UIC201601 and UIC201602Endocrine, nutritional and metabolic diseasesKCT0007411Korea United Pharm40
尚未招募
不适用
Study to investigate the effect of tamsulosin on the pharmacokinetic properties of tadalafil after oral administration in healthy male volunteersDiseases of The genitoruinary systemKCT0001243Chong Kun Dang16
尚未招募
不适用
Study to investigate the effect of tadalafil the pharmacokinetic properties of tamsulosinon after oral administration in healthy male volunteersDiseases of The genitoruinary systemKCT0001245Chong Kun Dang28